PrimeRFP - AI-Powered RFP Solutions
PrimeRFP SCOUT · Federal Contract Recompete Brief

15F06722F0000939Quadrivalent FLU vaccine in prefilled syringes — Glaxosmithkline LLC

Glaxosmithkline LLC holds $3.0B across 194 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent V797P2298D. The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Sep 30, 2022 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Division 1200
Awarding office
Glaxosmithkline LLC
Recipient
Sep 30, 2022
PoP end
$243K
Obligated
$243K
Potential
325412
NAICS
6515
PSC
1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Glaxosmithkline LLC — $90

Contract facts

Federal
Contract number15F06722F0000939
Also listed asV797P2298D-15F06722F0000939
AgencyDivision 1200
Awarding officeDivision 1200
Awarding agencyDepartment of Justice (DOJ)
Funding agencyDepartment of Justice (DOJ)
IncumbentGlaxosmithkline LLC
CAGE667E9
UEIFRHTPHMZMX47
NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6515
Parent IDIQ / IDVV797P2298D
Place of performanceWASHINGTON DC
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
PoP startSep 6, 2022
PoP end (current)Sep 30, 2022
Obligated$243K
Current value$243K
Potential value$243K

QUADRIVALENT FLU VACCINE IN PREFILLED SYRINGES, FEDERAL EXCISE TAX AND SHIPPING. IF QUADRIVALENT FLU VACCINE IS UNAVAILABLE, WILL CONSIDER TRIVALENT FLU VACCINE IN PREFILLED SYRINGES, FEDERAL EXCISE TAX AND SHIPPING. DELIVER MID SEPTEMBER 2022 TO ALL is a federal award for Division 1200 held by Glaxosmithkline LLC. Estimated value $243K ($243K obligated). Current period of performance ends Sep 30, 2022. Last award drew 1 bidder. Place of performance: WASHINGTON DC.

QUADRIVALENT FLU VACCINE IN PREFILLED SYRINGES, FEDERAL EXCISE TAX AND SHIPPING. IF QUADRIVALENT FLU VACCINE IS UNAVAILABLE, WILL CONSIDER TRIVALENT FLU VACCINE IN PREFILLED SYRINGES, FEDERAL EXCISE TAX AND SHIPPING. DELIVER MID SEPTEMBER 2022 TO ALL

Recompete timing

Public
● Past PoP end (1421 days ago)

Current PoP ended Sep 30, 2022 (1421 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Glaxosmithkline LLC — $3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($3.0B) · all agencies
Department of Health and Human Services (HHS)$3.0B · 100%Department of Defense (DOD)$1.7M · 0%Department of Veterans Affairs (VA)$1.5M · 0%Department of State (DOS)$1.2M · 0%
Open full company profile →

Related awards

Same parent · incumbent
75A50125F61019
FILL/FINISH DOD AS03 ADJUVANT CLIN 1006E
$491K
Aug 30, 2026
75A50126F61020
TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIOR…
$493K
Oct 29, 2026
15F06724F0001366
GSK TRAVEL VACCINES
$115K
Dec 31, 2026
15F06726F0000234
GSK VACCINES TERMS AND CONDITIONS REMAIN THE SAME - BPA 15F06722A0000187
$105K
Dec 31, 2026
75A50124F61014
THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL …
$18.4M
Feb 21, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 15F06722F0000939?

15F06722F0000939 (Quadrivalent FLU vaccine in prefilled syringes) is a Division 1200 award with a potential value of $243K, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 15F06722F0000939?

Division 1200 awarded 15F06722F0000939 to Glaxosmithkline LLC (potential $243K).

Who is the incumbent on 15F06722F0000939?

Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2022.

When does Glaxosmithkline LLC’s 15F06722F0000939 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 30, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/15F06722F0000939